Utilities for treatment-related adverse events in type 2 diabetes

This study aimed to capture UK societal utility values for health states associated with T2DM and treatment-related adverse events (AEs) to assess the burden of the disease and common AEs.

Quality of Life Decrements after Stroke

Objectives: To quantify which factors affect the quality of life valuations (QoL) of patients after stroke. Methods: 569 ischemic stroke patients were recruited into a retrospective, observational study in 10 teaching and regional hospitals across Belgium.

Bendamustine-rituximab: a cost-utility analysis in first-line treatment of indolent non-Hodgkin’s lymphoma in England and Wales

Objective: To evaluate the cost-effectiveness of bendamustine-rituximab (B-R) compared with CHOP-R and CVP-R as first-line treatment for patients with advanced indolent non-Hodgkin’s lymphoma (NHL).

Cost-effectiveness of adjunctive eptifibatide in patients undergoing coronary stenting in Germany

Objective: To determine the cost-effectiveness of adding eptifibatide to the standard treatment for selected high-risk patients undergoing coronary stenting in Germany. Furthermore, to investigate the impact of several extrapolation methods on the results.